Flu & Viruses
-
Anti-Ebola drug and antibody show promise
The anti-Ebola drug remdesivir has shown major promise in a global clinical trial involved Covid-19 patients, it was announced last night. Read more
-
Hope for Covid-19 inflammation therapy
Scientists are working on a new nanoparticle treatment for septic shock and uncontrolled inflammation that might help Covid-19 care. Read more
-
Blood plasma collection stepped up in therapy hope
Up to 10,000 units of blood plasma a week could be collected in the UK if it proves a successful therapy for the Covid-19 virus, it has been announced. Read more
-
Two nose cells likely Covid-19 entry points
Two specific cell types in the nose have been identified as likely initial infection points for Covid-19, according to a study published last night. Read more
-
Covid-19 antiviral drug trial unsuccessful – but vaccine trials launched
British doctors are to begin clinical trials of a vaccine against Covid-19 infection tomorrow – as trials of antiviral medicines continued to prove disappointing. Read more
-
Decoy protein could halt Covid-19
Scientists are developing decoy proteins that bind and trap the coronavirus to stop it infecting cells, it has been announced. Read more
-
German and UK parents most anti-vaccinations
One in 30 parents in Germany and the UK are anti-vaccinations regardless of which disease they are for, according to a new study. Read more
-
AI to aid Covid-19 planning
Trials have begun of a system that will use machine learning to help predict the demand for ICU beds and ventilators during the pandemic. Read more
-
Could overactive immune cells contribute to Covid-19 deaths?
Medical researchers from across the globe are investigating if overactive immune cells that produce Neutrophil Extracellular Traps (NETs) cause the most severe Covid-19 cases. Read more
-
Pandemic set to worsen in Americas
The Covid-19 pandemic is yet to hit the Americas with "full force," a senior health official warned yesterday as the USA continued to report record numbers of deaths. Read more